1-(3-溴苯基)-2-甲基-1-丙酮 | 2415-93-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-溴苯基)-2-甲基-1-丙酮
• 中文别名: 1-(3-溴苯基)-2-甲基丙-1-酮
• 英文名称: 1-(3-bromophenyl)-2-methylpropan-1-one
• CAS: 2415-93-2
• 化学式: C₁₀H₁₁BrO
• 分子量: 227.101
• InChiKey: NHXAYTCRAVHZQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  279.9±23.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(3-Bromophenyl)-2-methylpropan-1-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(3-Bromophenyl)-2-methylpropan-1-one
CAS number: 2415-93-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11BrO
Molecular weight: 227.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-溴苯基)-2-甲基-1-丙酮 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 Boc-L-alanine(2S)-hydroxypropylamide 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 24.25h， 以98%的产率得到(1R)-1-(3-bromophenyl)-2-methylpropan-1-ol
  参考文献：
  名称：

  双金属催化：钌和钾催化的位阻酮的不对称转移加氢

  摘要：

  提出了一种在转移加氢条件下不对称还原位阻酮的有效方案。以良好至优异的产率获得相应的手性醇，对映体过量值高达99％。研究了阳离子与还原反应中存在的碱的作用。与以前对该催化剂体系的研究相比，钾离子而不是锂离子显着增强了反应结果。

  DOI：

  10.1002/cctc.201500718
• 作为产物：
  描述：

  1-(3-bromophenyl)-2-methylpropan-1-ol 在 aluminum oxide 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以2.1 g的产率得到1-(3-溴苯基)-2-甲基-1-丙酮
  参考文献：
  名称：

  Dual Role of Alkynyl Halides in One-Step Synthesis of Alkynyl Epoxides

  摘要：

  It was demonstrated that alkynyl halides could serve as a source of Br+ and acetylide ions in the same transformation. This allowed for the efficient one-step preparation of alkynyl epoxides, important organic building blocks, from readily available starting materials.

  DOI：

  10.1021/ja806178r

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• CC Coupling of Ketones with Methanol Catalyzed by a N-Heterocyclic Carbene-Phosphine Iridium Complex
  作者：Xu Quan、Sutthichat Kerdphon、Pher G. Andersson

  DOI：10.1002/chem.201405990

  日期：2015.2.23

  carbene–phosphine iridium complex system was found to be a very efficient catalyst for the methylation of ketone via a hydrogen transfer reaction. Mild conditions together with low catalyst loading (1 mol %) were used for a tandem process which involves the dehydrogenation of methanol, CC bond formation with a ketone, and hydrogenation of the new generated double bond by iridium hydride to give the

  N-杂环卡宾-膦铱络合物系统被发现是通过氢转移反应使酮甲基化的非常有效的催化剂。在串联过程中使用温和的条件，同时降低催化剂的负载量（1 mol％），该过程涉及甲醇的脱氢，与酮形成的CC键以及氢化铱将新生成的双键氢化以得到烷基化产物。使用这种铱催化剂体系，可以合成许多支链酮，转化率和收率都非常好。
• Catalytic C₁  Alkylation with Methanol and Isotope-Labeled Methanol
  作者：Jan Sklyaruk、Jannik C. Borghs、Osama El-Sepelgy、Magnus Rueping

  DOI：10.1002/anie.201810885

  日期：2019.1.14

  A metal‐catalyzed methylation process has been developed. By employing an air‐ and moisture‐stable manganese catalyst together with isotopically labeled methanol, a series of D‐, CD3‐, and 13C‐labeled products were obtained in good yields under mild reaction conditions with water as the only byproduct.

  已经开发了一种金属催化的甲基化方法。通过将空气和水分稳定的锰催化剂与同位素标记的甲醇一起使用，在温和的反应条件下，以水为唯一副产物，可以高收率获得一系列D-，CD 3-和13 C-标记的产品。
• MODULATORS OF THE RELAXIN RECEPTOR 1
  申请人：The United States of America, as Represented by the Secretary, Dept. of Health & Human Services

  公开号：US20150119426A1

  公开（公告）日：2015-04-30

  Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

  本文揭示了人类松弛素受体1的调节剂，例如，公式（I）中的A、R1和R2如本文所定义，这些调节剂在治疗哺乳动物松弛素受体1介导的人类健康方面，例如心血管疾病中是有用的。还公开了一种包含药用适宜载体和本公开的至少一种化合物的组合物，以及一种用于治疗介导人类松弛素受体1的哺乳动物健康方面的干预方法。
• AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
  申请人：Rodgers James D.

  公开号：US20090233903A1

  公开（公告）日：2009-09-17

  The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及吲哚啉和环丁烷衍生物，以及它们的组合物、使用方法和制备方法，这些JAK抑制剂在治疗JAK相关疾病中很有用，包括炎症性和自身免疫性疾病，以及癌症。